Groundbreaking Platform First Applied to Rare Autoimmune
Disorder, IgG4-RD to Uncover New Treatment Targets
SOUTH
SAN FRANCISCO, Calif., Aug. 22,
2024 /PRNewswire-PRWeb/ -- Differentia Biotech, a
leader in model-informed drug development, is proud to announce the
launch of its innovative autoimmune disease platform. This platform
integrates Artificial Intelligence and Machine Learning (AI/ML)
with Quantitative Systems Pharmacology (QSP) extracting disease
understanding by combining insights from patient-specific
multiomics datasets and literature. This pioneering platform marks
a significant advancement in the understanding and treatment of
autoimmune diseases, enabling target identification and validation,
lead optimization, biomarker discovery and clinical trial
design.
The first application of Differentia Biotech's platform focuses
on IgG4-Related Disease (IgG4-RD), a rare and often misdiagnosed
autoimmune disorder, for which specific treatments are currently
missing due to insufficient understanding of its underlying
mechanisms. Differentia Biotech has successfully developed a
comprehensive disease model of IgG4-RD that maps the inter-cellular
communication network among key immune cells. This model elucidates
the dynamic interactions in healthy homeostasis and in the context
of IgG4-RD, revealing the distinctive immune system characteristics
associated with the disease state. Differentia Biotech utilized
this platform to evaluate various therapeutic interventions via
fast and scalable simulations and has identified targets that
effectively shift the disease state towards healthy homeostasis.
This innovative approach promises to transform the landscape of
autoimmune disease treatment by providing deeper insights into
disease mechanisms and accelerating the discovery of effective
therapies.
Key Features of the Differentia Biotech's Autoimmune Disorder
Platform:
- Advanced AI/ML Integration: Utilizes state-of-the-art machine
learning algorithms to analyze complex multi-omics biological data,
uncovering patterns and insights that are not discernible through
traditional methods.
- Quantitative Systems Pharmacology (QSP): Employs sophisticated
mathematical models to simulate disease processes and drug
interactions at a systems level, enabling precise identification of
potential therapeutic targets.
- First Application - IgG4-RD: The platform's success with
IgG4-RD underscores its potential to tackle other challenging
autoimmune diseases. The IgG4-RD model has already started yielding
promising targets for new treatments.
"Differentia's modeling platform was instrumental in our study
of IgG4-RD patients for clinical insights," said Dr Hui Gao from Department of Rheumatology, Peking
University International Hospital and Dr. Cuiping Pan from the Center for Intelligent
Medicine Research. "It helped to uncover complex immune
interactions in the patients, revealing enhanced B-cell
proliferation and differential regulation of cytokines in T-cell
subsets. Furthermore, we utilized Differentia's platform to model
treatment effects of numerous immune therapies, e.g., anti-CD20 B
cells, anti-IL4, and anti-IL6, which had been previously shown
beneficial in treating other autoimmune diseases. We are now
designing clinical trials to validate the off-label use of these
drugs for treating IgG4-RD. The collaboration with Differentia
helped us to prioritize drug candidates with a mechanistic
understanding, which accelerated the development of treatment
strategies for the patients. We are hopeful that these prioritized
drugs will have a therapeutic impact in this field."
"We are thrilled to introduce this groundbreaking platform,
which represents a new era in the fight against autoimmune
disorders," said Kas Subramanian, CEO of Differentia Biotech. "By
combining the predictive power of AI/ML with the robust analytical
capabilities of QSP, we are not only enhancing our understanding of
these complex diseases but also paving the way for the development
of more effective treatments."
Differentia Biotech invites biotech and pharmaceutical companies
and research organizations with a focus on autoimmune diseases to
explore the potential applications of this platform to their
specific areas of interest. By partnering with Differentia Biotech,
stakeholders can leverage this powerful tool to drive their
research and development efforts towards groundbreaking discoveries
and innovative therapies.
For partnership inquiries and more information about Differentia
Biotech's autoimmune disorder platform, please contact:
Lorenz Huebner
V.P. Customer Solutions
Differentia Biotech
lorenz.huebner@differentiabio.com
Ph: +49 151 290 35213
www.differentiabio.com
About Differentia Biotech:
Differentia provides modeling and simulation services to
biopharmaceutical companies delivering knowledge-based insights to
improve drug development outcomes. Backed by Differentia's
proprietary data pool and cutting-edge AI/ML analytics, we empower
biopharmaceutical companies to accelerate drug development and
shape the future of healthcare.
Media Contact
Lorenz Huebner, Differentia
Biotech, 49 151 290 35213, lorenz.huebner@differentiabio.com,
www.differentiabio.com
View original
content:https://www.prweb.com/releases/differentia-biotech-launches-cutting-edge-autoimmune-disorder-platform-combining-aiml-with-qsp-302226178.html
SOURCE Differentia Biotech